242 related articles for article (PubMed ID: 22618082)
1. Tuning glycosidase inhibition through aglycone interactions: pharmacological chaperones for Fabry disease and GM1 gangliosidosis.
Aguilar-Moncayo M; Takai T; Higaki K; Mena-Barragán T; Hirano Y; Yura K; Li L; Yu Y; Ninomiya H; García-Moreno MI; Ishii S; Sakakibara Y; Ohno K; Nanba E; Ortiz Mellet C; García Fernández JM; Suzuki Y
Chem Commun (Camb); 2012 Jul; 48(52):6514-6. PubMed ID: 22618082
[TBL] [Abstract][Full Text] [Related]
2. The potential action of galactose as a "chemical chaperone": increase of beta galactosidase activity in fibroblasts from an adult GM1-gangliosidosis patient.
Caciotti A; Donati MA; d'Azzo A; Salvioli R; Guerrini R; Zammarchi E; Morrone A
Eur J Paediatr Neurol; 2009 Mar; 13(2):160-4. PubMed ID: 18571950
[TBL] [Abstract][Full Text] [Related]
3. A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis.
Takai T; Higaki K; Aguilar-Moncayo M; Mena-Barragán T; Hirano Y; Yura K; Yu L; Ninomiya H; García-Moreno MI; Sakakibara Y; Ohno K; Nanba E; Ortiz Mellet C; García Fernández JM; Suzuki Y
Mol Ther; 2013 Mar; 21(3):526-32. PubMed ID: 23337983
[TBL] [Abstract][Full Text] [Related]
4. (5aR)-5a-C-Pentyl-4-epi-isofagomine: A powerful inhibitor of lysosomal β-galactosidase and a remarkable chaperone for mutations associated with GM1-gangliosidosis and Morquio disease type B.
Front S; Biela-Banaś A; Burda P; Ballhausen D; Higaki K; Caciotti A; Morrone A; Charollais-Thoenig J; Gallienne E; Demotz S; Martin OR
Eur J Med Chem; 2017 Jan; 126():160-170. PubMed ID: 27750150
[TBL] [Abstract][Full Text] [Related]
5. N-Substituted 5-amino-1-hydroxymethyl-cyclopentanetriols: A new family of activity promotors for a G
Schalli M; Tysoe C; Fischer R; Pabst BM; Thonhofer M; Paschke E; Rappitsch T; Stütz AE; Tschernutter M; Windischhofer W; Withers SG
Carbohydr Res; 2017 Apr; 443-444():15-22. PubMed ID: 28319682
[TBL] [Abstract][Full Text] [Related]
6. DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human G(M1)-gangliosidosis fibroblasts.
Fantur K; Hofer D; Schitter G; Steiner AJ; Pabst BM; Wrodnigg TM; Stütz AE; Paschke E
Mol Genet Metab; 2010 Jul; 100(3):262-8. PubMed ID: 20409738
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of pharmacological chaperoning for human β-galactosidase.
Suzuki H; Ohto U; Higaki K; Mena-Barragán T; Aguilar-Moncayo M; Ortiz Mellet C; Nanba E; Garcia Fernandez JM; Suzuki Y; Shimizu T
J Biol Chem; 2014 May; 289(21):14560-8. PubMed ID: 24737316
[TBL] [Abstract][Full Text] [Related]
8. 4-epi-Isofagomine derivatives as pharmacological chaperones for the treatment of lysosomal diseases linked to β-galactosidase mutations: Improved synthesis and biological investigations.
Front S; Almeida S; Zoete V; Charollais-Thoenig J; Gallienne E; Marmy C; Pilloud V; Marti R; Wood T; Martin OR; Demotz S
Bioorg Med Chem; 2018 Nov; 26(20):5462-5469. PubMed ID: 30270003
[TBL] [Abstract][Full Text] [Related]
9. A new type of pharmacological chaperone for G
Schalli M; Weber P; Tysoe C; Pabst BM; Thonhofer M; Paschke E; Stütz AE; Tschernutter M; Windischhofer W; Withers SG
Bioorg Med Chem Lett; 2017 Aug; 27(15):3431-3435. PubMed ID: 28600215
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of multimeric pyrrolidine iminosugar inhibitors of human β-glucocerebrosidase and α-galactosidase A: First example of a multivalent enzyme activity enhancer for Fabry disease.
Martínez-Bailén M; Carmona AT; Cardona F; Matassini C; Goti A; Kubo M; Kato A; Robina I; Moreno-Vargas AJ
Eur J Med Chem; 2020 Apr; 192():112173. PubMed ID: 32146376
[TBL] [Abstract][Full Text] [Related]
11. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
Suzuki Y
Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
[TBL] [Abstract][Full Text] [Related]
12. 5-Fluoro derivatives of 4-epi-isofagomine as D-galactosidase inhibitors and potential pharmacological chaperones for GM1-gangliosidosis as well as Fabry's disease.
Thonhofer M; Gonzalez Santana A; Fischer R; Torvisco Gomez A; Saf R; Schalli M; Stütz AE; Withers SG
Carbohydr Res; 2016 Feb; 420():6-12. PubMed ID: 26717544
[TBL] [Abstract][Full Text] [Related]
13. A fluorescent probe for GM1 gangliosidosis related β-galactosidase: N-(dansylamino)hexylaminocarbonylpentyl-1,5-dideoxy-1,5-imino-D-galactitol.
Fröhlich RF; Fantur K; Furneaux RH; Paschke E; Stütz AE; Wicki J; Withers SG; Wrodnigg TM
Bioorg Med Chem Lett; 2011 Nov; 21(22):6872-5. PubMed ID: 21974950
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies.
Germain DP; Fan JQ
Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S111-7. PubMed ID: 20040321
[TBL] [Abstract][Full Text] [Related]
15. Molecular interaction of imino sugars with human alpha-galactosidase: Insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease.
Sugawara K; Tajima Y; Kawashima I; Tsukimura T; Saito S; Ohno K; Iwamoto K; Kobayashi T; Itoh K; Sakuraba H
Mol Genet Metab; 2009 Apr; 96(4):233-8. PubMed ID: 19181556
[TBL] [Abstract][Full Text] [Related]
16. The pharmacological chaperone N-n-butyl-deoxygalactonojirimycin enhances β-galactosidase processing and activity in fibroblasts of a patient with infantile GM1-gangliosidosis.
Mohamed FE; Al Sorkhy M; Ghattas MA; Al-Gazali L; Al-Dirbashi O; Al-Jasmi F; Ali BR
Hum Genet; 2020 May; 139(5):657-673. PubMed ID: 32219518
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement for GM1-gangliosidosis: Uptake, lysosomal activation, and cellular disease correction using a novel β-galactosidase:RTB lectin fusion.
Condori J; Acosta W; Ayala J; Katta V; Flory A; Martin R; Radin J; Cramer CL; Radin DN
Mol Genet Metab; 2016 Feb; 117(2):199-209. PubMed ID: 26766614
[TBL] [Abstract][Full Text] [Related]
18. 2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease.
Kato A; Yamashita Y; Nakagawa S; Koike Y; Adachi I; Hollinshead J; Nash RJ; Ikeda K; Asano N
Bioorg Med Chem; 2010 Jun; 18(11):3790-4. PubMed ID: 20457528
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of C-5a-chain extended derivatives of 4-epi-isofagomine: Powerful β-galactosidase inhibitors and low concentration activators of GM1-gangliosidosis-related human lysosomal β-galactosidase.
Thonhofer M; Weber P; Santana AG; Fischer R; Pabst BM; Paschke E; Schalli M; Stütz AE; Tschernutter M; Windischhofer W; Withers SG
Bioorg Med Chem Lett; 2016 Mar; 26(5):1438-42. PubMed ID: 26838810
[TBL] [Abstract][Full Text] [Related]
20. Impaired elastic-fiber assembly by fibroblasts from patients with either Morquio B disease or infantile GM1-gangliosidosis is linked to deficiency in the 67-kD spliced variant of beta-galactosidase.
Hinek A; Zhang S; Smith AC; Callahan JW
Am J Hum Genet; 2000 Jul; 67(1):23-36. PubMed ID: 10841810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
